Perspectives on cancer experiences with oncologist Dr. Willie Goffney

American Cancer Society

Share This Post

Feb 2023: Check out this tweet from the American Cancer Society that shares a conversation with Dr. Willie Goffney about her perspective on cancer. A tweet says, “Join Adam Lopez, host of Candid Conversations, as he discusses personal and professional perspectives on cancer experiences with oncologist Dr. Willie Goffney and community leader Tracie Kimbrough as part of the ongoing Diversity in Science campaign.” Check out this tweet from ACC below.

You can also watch the entire conversation on YouTube.


Check out the entire conversation on YouTube.

The American Cancer Society is the leading cancer-fighting organization with a vision of ending cancer as we know it, for everyone. We are the only organization working to improve the lives of people with cancer and their families through advocacy, research, and patient support, to ensure everyone has an opportunity to prevent, detect, treat, and survive cancer. Learn more about who we are, what we do, and our plans for the future by exploring the areas below.

Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020 (1). The most common in 2020 (in terms of new cases of cancer) were:

  • breast (2.26 million cases);
  • lung (2.21 million cases);
  • colon and rectum (1.93 million cases);
  • prostate (1.41 million cases);
  • skin (non-melanoma) (1.20 million cases); and
  • stomach (1.09 million cases).

The most common causes of cancer deaths in 2020 were:

  • lung (1.80 million deaths);
  • colon and rectum (916 000 deaths);
  • liver (830 000 deaths);
  • stomach (769 000 deaths); and
  • breast (685 000 deaths).

Each year, approximately 400,000 children develop cancer. The most common cancers vary between countries. Cervical cancer is the most common in 23 countries. 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy